Immune modulation by dendritic-cell-based cancer vaccines.

about

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

P2860

Q39415827-CA2AAAB4-991F-4F1A-B3A5-D3E2A2C947ED

P2860

Immune modulation by dendritic-cell-based cancer vaccines.

Item

http://www.wikidata.org/entity/Q39147683

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Immune modulation by dendritic-cell-based cancer vaccines.

@en

Immune modulation by dendritic-cell-based cancer vaccines.

@nl

type

Item

label

Immune modulation by dendritic-cell-based cancer vaccines.

@en

Immune modulation by dendritic-cell-based cancer vaccines.

@nl

prefLabel

Immune modulation by dendritic-cell-based cancer vaccines.

@en

Immune modulation by dendritic-cell-based cancer vaccines.

@nl

P1476

Immune modulation by dendritic-cell-based cancer vaccines.

@en

P2093

Ashok Kumar Vaid

http://www.w3.org/2001/XMLSchema#string

Bandana Sharan

http://www.w3.org/2001/XMLSchema#string

Chaitanya Kumar

http://www.w3.org/2001/XMLSchema#string

Minish Jain

http://www.w3.org/2001/XMLSchema#string

Poonamalle Parthasarathy Bapsy

http://www.w3.org/2001/XMLSchema#string

Sakshi Kohli

http://www.w3.org/2001/XMLSchema#string

Venkata Sathya Suresh Attili

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

Antigen presentation and T cell stimulation by dendritic cells

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

mTOR regulates memory CD8 T-cell differentiation

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Engineering opportunities in cancer immunotherapy

Adoptive T-cell therapy for cancer: The era of engineered T cells

P2888

s12038-017-9665-x

P304

161-173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12038-017-9665-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28229976

http://www.w3.org/2001/XMLSchema#string

Immune modulation by dendritic-cell-based cancer vaccines.

about

P2860

P2860

Immune modulation by dendritic-cell-based cancer vaccines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698